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1. Introduction  
A great advance in understanding mechanosensing and mechanotransduction of bone tissue 
has occurred in the past years. However, a clear answer is yet to come. There is plentiful 
evidence that most cells in human body are able to sense their mechanical environment, 
including osteoblasts and osteocytes. Li et al. found that marrow stromal cells change their 
proliferation rate and gene expression patterns in response to mechanical stimulation (Li et al, 
2004). Ehrlich and Lanyon mention that osteocytes produce significantly higher levels of  PGE2 
(prostaglandin E2) and PGI2 (prostacylin) than osteoblasts and in vivo inhibition of 
prostaglandins prevents bone adaptation in response to mechanical strains (Ehrlich and 
Lanyon, 2002). Further, nitric oxide NO is also a mediator of mechanically induced bone 
formation. It is released, similarly, as prostanoids, in higher levels after exposure to 
physiological levels of mechanical loading. Moreover, Rubin discovered that dynamic loading 
down-regulates osteoclastic formation (Rubin et al, 2000) (more precisely, the strained bone 
cell downregulates its expression of RANKL (Rubin et al, 2004)), which suggests that 
mechanical forces play an important role in bone adaptation process. 
Candidate mechanoreceptors within a cell are stretch-activated channels, integrins 
(membrane spanning proteins that couple the cell to its extracellular environment), 
connexins (membrane spanning proteins that form channels that allow the direct exchange 
of small molecules with adjacent cells - including intercellular communication via gap 
junctions), and membrane structure (Rubin, 2006). Nowadays, there is also a completely 
different possible explanation for transformation mechanical signal into a biochemical 
function. Valle et al. explain in their review that only a proper mechanical loading may lead 
to exposure of binding sites and thus enabling further biochemical processes to proceed 
(Valle, 2007). Most probably multiple mechanosensors are involved in receiving mechanical 
signals. Moreover, there are other studies showing the importance of many other 
mechanisms beside those mentioned above (Lemaire et al, 2004). 
On tissue level, it is clear that mechanical loading is important in the bone remodelling 
process. Heřt described an interaction between the mechanical stimulation of local cells and 
the bone adaptation process in the 1970s (Heřt et al, 1972), Frost observed the same 
behaviour in his clinical praxis and summed it up in his „Utah paradigm“ (Frost, 2004). 
More recently, the fundamental importance of dynamic loading was accepted. Comparison 
of the static versus the dynamic loading effects on bone remodelling is given in a nice and 
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inspectional review by Ehrlich and Lanyon (2002). Further, Robling provides experimental 
results that confirm the essential importance of the dynamic loading (Robling, 2006). It is 
worth mentioning that Heřt referred to this fact in his observations more than 35 years ago 
(Heřt et al, 1972). 
From the phenomenological relations for the rate of chemical reaction based on classical 
irreversible thermodynamics including coupling with mechanical processes, it was shown 
that, although tissues are exposed to all variety of mechanical factors: straining, shear, 
pressure, and even dynamic electric fields, the volume variation rate is the most important 
mechanical stimulus driving the processes in them (Klika, 2010). However, we believe that 
shear rate might be important for triggering the process. (for details see (Klika, 2010; Klika and 
Maršík, 2009)). Thus, in the presented manuscript, the mechanical stimulation of bone 
remodelling was assumed to be proportional to rate of volume change. As it will be seen from 
the features and results of the model, it seems to capture the response of bone to changes of its 
mechanical environment on tissue level. Probably, the other ways of mechanosensing are 
controlling the triggering of bone remodelling process in a given loci. We realize that 
biochemical reactions are initiated and influenced primarily by genetic effects and then by 
external biomechanical effects (stress changes). The aim of the presented thermodynamic 
model is to combine biological and biomechanical factors whereas currently available models 
of bone remodelling focus only on one of these factors which is actually the reason why this 
model was developed. It should provide an estimate of the effects of increased physical 
activity on quality of bone even in several disease states. Such a model may also reflect 
changes in remodelling behaviour resulting from pathological changes to the bone metabolism 
or from hip joint replacement and also may help for better assessment of the risk of 
osteoporosis-related fractures (Lindsay, 2003). Preliminary version of the mentioned approach 
has been published by our team in the past but not until this considerably improved version 
was the model applicable to praxis (both qualitative and quantitative results) (Klika and 
Maršík, 2010; Klika et al., 2010) which is here being extended. 
1.1 Available models of bone remodeling 
With the development of computer-aided strategies and based on the knowledge of bone 
geometry, applied forces, and elastic properties of the tissue, it may be possible to calculate 
the mechanical stress transfer inside the bone (Finite Elements analysis or FE analysis). The 
change of stresses is followed by a change in internal bone density distribution. This allows 
to formulate mathematical models that can be used to study functional adaptation 
quantitatively and furthermore, to create the bone density distribution patterns (Beaupré et 
al, 1990; Carter, 1987). Such mathematical models have been built in the past. Since they 
calculate just mechanical transmission inside the bone and not considering cell-biologic 
factors of bone physiology, they just partially correspond to the reality seen in living 
organisms. Basically, there are essentially two groups of models for bone remodelling. One 
assumes that the mechanical loading is the dominant effect, almost to the exclusion of other 
factors, and treatment of biochemical effects are included in parameter with no physical 
interpretation (e.g. Beaupré et al, 1990; Carter, 1987; Huiskes et al, 1987; Ruimerman et al, 
2005; Turner et al, 1997). The results or predictions of these models yield the correct density 
distribution patterns in physiological cases. However, they have a limited ability to simulate 
disease. The second group, the biochemical models, consider control mechanisms of bone 
adaptation in great detail, but with limited possibilities for including mechanical effects that 
are known to be essential (Komarova et al, 2003; Lemaire et al, 2004). We realize that 
biochemical reactions are initiated and influenced primarily by genetic effects and then by 
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external biomechanical effects (stress changes). Our thermodynamic model enables to 
combine biological and biomechanical factors (Klika and Maršík, 2010). Such a model may 
also reflect changes in remodelling behaviour resulting from pathological changes to the 
bone metabolism or from hip joint replacement. However, it is a model and thus it is a great 
simplification of the complex process of bone remodelling. In this chapter, a more detailed 
description of biochemical control mechanisms will be added to the mentioned model (Klika 
and Maršík, 2010; Klika et al, 2010) which in turn leads to possibility to study several 
concrete bone related diseases using this model. 
1.2 Simulation of diseases and of their treatment 
In our previous work, the influence of mechanical stimulation on (chemical) interactions in 
general was studied and it was shown how to comprise this effect into a model of studied 
biochemical processes (Klika and Maršík, 2009; Klika, 2010). These findings were used to 
describe the bone remodelling phenomenon (Klika and Maršík, 2010; Klika et al, 2010; 
Maršík et al, 2010). In this chapter, an extension of the mentioned bone remodelling model 
(influences of concrete biochemical factors) will be presented where the essential 
significance of dynamic loading will still be apparent. 
Firstly, fundamental control factors will be mentioned. As was mentioned in the 
introduction, the RANKL-RANK-OPG pathway is essential in the bone remodelling control. 
Osteoprotegerin (OPG) inhibits binding of ligand RANKL to receptor RANK and thus 
prevents osteoclastogenesis. Since osteoclasts are the only resorbing agents in bone, 
osteoprotegerin “protects bone” (osteo-protege). Further, one of the major problems 
connected to bone remodelling is a rapid bone loss after menopause that affects a significant 
portion of women after 50 years of age. Menopause is linked to a rapid decrease in estrogen 
levels. And because estrogen significantly affects bone density, it would be beneficial to be 
able to simulate the influence of estrogen levels on the bone remodelling process. Similarly, 
the parathyriod hormone PTH, tumour growth factor TGF-β1, and nitric oxide NO play a 
significant role during the bone adaptation process. 
PTH causes a release of calcium from the bone matrix and induces MNOC differentiation from 
precursor cells, estrogen has complex effects with final outcome in decreasing bone resorption 
by MNOC, calcitonin decreases levels of blood calcium by inhibiting MNOC function, and 
osteocalcin inhibits mineralisation (Sikavitsas et al, 2001). The discovery of the RANKL-
RANK-OPG pathway enabled a more detailed study of the control mechanisms of bone 
remodelling. Robling et al. states that all PTH, PGE (prostaglandin), IL (interleukin), and 
vitamin D are “translated” by corresponding cells (osteoblasts) into RANKL levels (Robling et 
al, 2006). Further, nitric oxide NO is known to be a strong inhibitor of bone resorption and 
recently it has been known that it works in part by suppressing the expression of RANKL and, 
moreover, by promoting the expression of OPG (Robling et al, 2006). Both these effects 
eventually lead to a decrease of numbers of active osteoclasts MNOC, which in turn causes 
decrease of bone resorption. Kong and Penninger mention that the OPG expression is induced 
by estrogen (Kong and Penninger, 2000). Boyle et al. add that OPG production by osteoblasts 
is based on anabolic stimulation from TGF-β or estrogen (Boyle et al, 2003). Martin also deals 
with the question how hormones and cytokines influence contact-dependent regulation of 
MNOC by osteoblasts. He summaries results from the carried out experiments (mainly in 
vitro) that PTH, IL-11, and vitamin D (1.25(OH)2D3 more precisely) promotes RANKL 
formation, which in turn increases osteoclastogenesis (Martin, 2004). 
RANKL-RANK-OPG pathway mediates many of these above mention biochemical factors. 
Moreover, RANKL levels also reflect microcrack density. Hence, it is essential to incorporate 
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this pathway into our model. The connection will be enabled through the amount RANKL-
RANK bonds that are one of the components of developed model, noted as RR, see (Klika 
and Maršík, 2010). 
2. Methods 
Bone remodelling is a very complex mechanism. It is necessary to make reasonable 
simplification to identify the essential control mechanisms. The used model covers the 
accepted crucial features (Klika and Maršík, 2010). 
In this manuscript, several schemes for treating cellular interactions (as interactions among 
mixtures of chemical substances) are proposed, which are commonly used in similar problems 
(Keener and Sneyd, 2009; Lemaire et al, 2004). In our model, individual components of bone 
are substrates and products of biochemical interactions, whose rates are determined by the 
difference in chemical potentials. The affinity and chemical potential are (in simpler cases) 
proportional to the logarithm of the molar concentration of the involved substances (deGroot 
and Mazur, 1962). Here we actually use a modified version of this law of mass action with the 
additional effect of dynamic loading on the interaction rates (Klika, 2010; Klika and Maršík, 
2009). The law of mass action is frequently used in modelling biological processes (Keener and 
Sneyd, 2009). However, it is only a simplified model that can be justified by agreement 
between calculated data and clinical observations. From the submitted results, it can be seen 
that features of the presented model are consistent with clinical and experimental data. 
2.1 Incorporation of RANKL-RANK-OPG pathway into the bone remodelling model   
A new model for RANKL-RANK-OPG chain kinetics has been formulated and added (Klika et 
al., 2010) to the mentioned model of bone remodelling (Klika and Maršík, 2010). This section is 
being RANKL is a ligand molecule and binds to RANK forming a bond, here noted as ܴܴ and 
its molar concentration as [RR], between osteoblasts and precursors of osteoclasts. Osteoblasts 
also secrete a decoy receptor osteoprotegerin OPG that binds with high affinity to RANKL and 
thus prevents the needed connection between osteoblasts and osteoclastic precursors. 
The reaction scheme of interaction of the mentioned molecules can be described as follows:  ܴܣܰܭܮ + ܴܣܰܭ ୩±భርሮ ܴܴ,ܴܣܰܭܮ + ܱܲܩ ୩±మርሮ ܴ ୧ܱ୬ୟୡ୲୧୴ୣ, (1)
 where ܴ ୧ܱ୬ୟୡ୲୧୴ୣ represents the bond between the decoy OPG and ligand RANKL. Using 
the law of mass action (Klika and Maršík, 2009) we may infer kinetics of the above 
mentioned interactions. Only the simplification, when assuming a relation between forward 
and backward reaction rates ݇ା௜ ≫ ݇ି௜, is not applicable here. We get  d݊ோ஺ே௄௅d߬ = −݊ோ஺ே௄௅ሺߚୖ୏ୖୖ୓ + ݊ோ஺ே௄௅ − ݊ை௉ீሻ +																				+ߜିଵୖୖ୓ሺߚୖୖୖୖ୓ − ݊ோ஺ே௄௅ + ݊ை௉ீሻ −																																				−ߜାଶୖୖ୓݊ோ஺ே௄௅݊ை௉ீ + ߜିଶୖୖ୓ሺߚୖ୓ୖୖ୓ − ݊ை௉ீሻ,d݊ை௉ீd߬ = −ߜାଶୖୖ୓݊ோ஺ே௄௅݊ை௉ீ + ߜିଶୖୖ୓ሺߚୖ୓ୖୖ୓ − ݊ை௉ீሻ,
 (2)
 where  
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ߜିଵୖୖ୓ = ݇ିଵ݇ାଵ[RANKLୱ୲ୟ୬ୢ] ,ߜିଶୖୖ୓ 				= ݇ିଶ݇ାଵ[RANKLୱ୲ୟ୬ୢ] ,ߜାଶୖୖ୓ 				= ݇ାଶ݇ାଵ ,ߚୖ୓ୖୖ୓ 				= ܥୖ୓[RANKLୱ୲ୟ୬ୢ] = [RO଴] + [OPG଴][RANKLୱ୲ୟ୬ୢ] ,ߚୖୖୖୖ୓ = ܥୖୖRANKLୱ୲ୟ୬ୢ = [RR଴] + [RANKL଴] − [OPG଴][RANKLୱ୲ୟ୬ୢ] .
 (3)
Again ݇±௜ are reaction rate coefficients, ߜ௜ are interaction rates, and ߚ௝ୖ ୖ୓ represents the 
normalised initial molar concentrations of corresponding substances, denoted with index 0 
and finally [RANKLୱ୲ୟ୬ୢ] represents standard serum level of RANKL used for normalisation 
of molar concentrations of substance ݅, ݊௜. All the parameters have evidently a physical 
interpretation and are measurable. However, hardly any such in vivo data for humans is 
available. Fortunately, the recent progress in the understanding of bone remodelling control 
enabled in vitro studies of individual factors. 
Quinn et al. studied the influence of RANKL and OPG concentration on a number of 
osteoclasts (more precisely, TRAP positive multinucleated osteoclasts) in a dose-dependent 
way (Quinn et al, 2001). We would like to use this data to determine the above mentioned 
parameters of the RANKL-RANK-OPG model. Because the carried out experiments are 
studying effects of RANKL and OPG separately, the reaction scheme (1) may be splitted into 
two separate reactions for parameter setting. This is convenient because the kinetics of a 
single biochemical reaction can be described using a single differential equation (in this case 
non-linear). Moreover, both normalised differential equations corresponding to these two 
reactions can be written in the same form:  
 ݔሶ = −ܣݔଶ − ܤݔ + ܥ,				ܣ > Ͳ, ܥ > Ͳ, (4) 
where ܣ = ͳ, ܤ = ߚୖ୏ + ߜିଵ, ܥ = ߜିଵߚୖୖ for the RANKL reaction and ܣ = ߜାଶ, ܤ =ߜାଶߚୖ୅୒୏୐ + ߜିଶ, ܥ = ߜିଶߚୖ୓ for OPG reaction. The normalised form is also useful because it 
decreases the number of unknown parameters. The differential equation (4) has the 
following solution for positive constants ܣ, ܥ and for initial value ݔ଴:  
ݔሺ߬ሻ = ൦ ʹܣ√ܤଶ + Ͷܣܥ ൮ͳ + ͳ + ʹܣ√ܤଶ + Ͷܣܥ ቀݔ଴ + ʹܤܣቁͳ − ʹܣ√ܤଶ + Ͷܣܥ ቀݔ଴ + ʹܤܣቁ ݁√஻మାସ஺஼ఛ൲൪
ିଵ ⋅
⋅ ൦൬ͳ − ܤ√ܤଶ + Ͷܣܥ൰ͳ + ʹܣ√ܤଶ + Ͷܣܥ ቀݔ଴ + ʹܤܣቁͳ − ʹܣ√ܤଶ + Ͷܣܥ ቀݔ଴ + ʹܤܣቁ ݁√஻మାସ஺஼ఛ − ܤ√ܤଶ + Ͷܣܥ − ͳ൪ .
 (5)
Because we know the analytic form of function describing the kinetics of RANKL (and 
OPG), we may use the least square method for determination of the unknown parameters 
according to the carried out experiments. Data from the Quinn et al. in vitro experiment 
relates RANKL (and OPG) concentration to MNOC concentration (the number of osteoclasts 
per well). The mentioned reaction scheme (1) of RANKL-RANK-OPG interaction has an 
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output product denoted as ܴܴ. Thus, to be able to use the mentioned data from Quinn et al., 
we need to relate RANKL-RANK bonds ([RR]) to the number of osteoclasts ([MNOC]). To get 
a precise prediction of this relationship from the presented model we would also need to 
know the analytical solution of the system of ODEs that describe the bone remodelling 
process (Klika and Maršík, 2010), which is not possible. On the other hand, the interaction 
that describes the relation between RANKL-RANK bonds and MNOC concentration is the 
first one in our bone remodelling scheme (Klika and Maršík, 2010) and it will be assumed 
that the number of formed and active osteoclasts is proportional to the ܴܴ concentration. It 
means that it was assumed that in vitro, where no remodellation occurs, the formation of 
osteoclasts may be described by:  ܴܴ	⇄ ܯܱܰܥ. 
This assumption will be used just for purposes of parameter setting and from final results it 
will be possible to see if this simplification was too great or not. 
The next issue we have to deal with is finding a possible relation between in vitro and in 
vivo data. In vivo ones are more or less unavailable, especially in such a detail that is needed 
for parameter setting. Further, determination of standard serum levels of OPG and RANKL 
is needed. The problem is that in most cases in vitro concentrations have to be much higher 
to reach a similar effect as in vivo. Moreover, no such relation may exist. It will be assumed 
that there is a correspondence among these two approaches and that it is linear, i.e. in vivo 
data can be gained from in vitro after appropriate scaling of concentrations. 
The search for standard serum levels of osteoprotegerin and RANKL was not simple. Studies 
differ greatly in the presented values. Kawasaki et al states that the standard level of 
osteoprotegerin is ʹͷͲ ௣௚ఓ௟  (Kawasaki et al, 2006) and Moschen et al. mention ͺͲͲ ௣௚ఓ௟  (Moschen 
et al, 2005). Further, Eghbali-Fatourechi et al. determined OPG serum levels to be ʹ.Ͳͷ ௣௠௢௟௟  
(Eghbali-Fatourechi et al, 2003). The probable cause of these discrepancies lies in differently 
used techniques of gaining osteoprotegerin and measuring its concentration. Kawasaki et al. 
measured the amount of RANKL in gingival crevicular fluid, Moschen et al. performed 
collonic explant cultures from biopsies and consequently measured RANKL and OPG levels 
using an ELISA kit, and Eghbali-Fatourechi used a different cell preparation technique 
followed by measurement with an ELISA kit. One of the manufacturers of the ELISA kit for 
assessment OPG levels cites several studies on OPG levels in humans and also submits results 
from their own research (Elisa OPG kit, 2006). At least all these measurements are carried out 
by the same measurement technique and are comparable. Therefore, we set standard OPG and 
RANKL levels according to data that are there referred to - [RANKLୱ୲ୟ୬ୢ] = Ͳ.ͺͶ ௣௠௢௟௟ = ͷͷ ⋅Ͳ.ͺͶ ௣௚௠௟ = Ͷ͸.ʹ ௣௚௠௟ and [OPGୱ୲ୟ୬ୢ] = ͳ.ͺ ௣௠௢௟௟ = ʹͲ ⋅ ͳ.ͺ ௣௚௠௟ = ͵͸ ௣௚௠௟ in serum (Kudlacek et al, 
2003), where the knowledge of molecular weights ܯ ୖܹ୅୒୏୐ = ͷͷͳͲଷ, ܯ ୓ܹ୔ୋ = ʹͲͳͲଷ was 
used (Elisa OPG kit, 2006; RANKL product data sheet, 2008). Now it is needed to find a 
reasonable relation with in vitro data from Quinn et al that will be used for the least squares 
method for parameter estimation. The following consideration will be used: the physiological 
range of levels of OPG and RANKL will be found and consequently related to studied 
effective in vitro range by Quinn. OPG serum levels found in human are ͳʹ-ͳ͵ͺ ௣௚௠௟ = Ͳ.͸-͸.ͻ ௣௠௢௟௟  and RANKL serum levels are 0-ʹͷͲ ௣௚௠௟ = Ͳ-Ͷ.ͷͷ ௣௠௢௟௟  with standard values of Ͳ.ͺͶ ௣௠௢௟௟  
for RANKL and ͳ.ͺ ௣௠௢௟௟  for OPG, respectively. When we relate these values to the in vitro 
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ranges of RANKL 0-ͷͲͲ ௡௚௠௟ and of OPG 0-͵Ͳ ௡௚௠௟, we get the in vitro equivalents for standard 
values: [RANKL୧୬୴୧୲୰୭ୱ୲ୟ୬ୢ] = ͻʹ.͵ ௡௚௠௟, [OPG୧୬୴୧୲୰୭ୱ୲ୟ୬ୢ] = ͹.ͺ͵ ௡௚௠௟. 
A list of parameters that will be determined by least squares from the RANKL experiment 
are the following:  ߜିଵୖୖ୓, ߬଻ୢୟ୷ୱୖୖ୓ , ݊ோ௄బ , ݊ோோబ , 
where ߬଻ୢୟ୷ୱୖୖ୓  is the dimensionless time that corresponds to 7 days. Before the parameter 
setting is by curve fitting (least square method) is carried out, it is reasonable to have at least 
some estimation of parameter values. Because the normalisation was done by division with 
term ݇ାଵ[RANKLୱ୲ୟ୬ୢ]ଶ and from (3), we get:  ߬଻ୢୟ୷ୱୖୖ୓ = ݐ݇ାଵܥୖୖ|௧ୀ଻ௗ௔௬௦ = ͸ ͳͲହͳͲ଻ͳͲିଵଶ ≈ ͳͲ଴,݊ோோబ 				≈ ͳͲ଴,݊ோ௄బ 				≈ ͳͲ଴,ߜିଵ౎౎ో = ݇ିଵ݇ାଵ[RANKLୱ୲ୟ୬ୢ] ≈ ݇ିଵͳͲହ,
 
where the value of ݇ାଵ was estimated from the parameter setting in the bone remodelling 
model, standard value of RANKL [RANKLୱ୲ୟ୬ୢ] ≈ ͳ ௣௠௢௟௟  was mentioned above, and the ݇ିଵ 
value may be anywhere in ሺͲ,ͳͲ଻ሻ but most probably lower than one. 
The least square method with the used data from Quinn et al. (Quinn et al, 2001) and the 
analytic function as described above gives the following estimates:  
 ߜିଵୖୖ୓ = Ͷ.ͻʹͳͲି଺, ߬଻ୢୟ୷ୱୖୖ୓ = Ͷ.͸Ͷ, ݊ோ௄బ = ͳ.Ͳ͵͹, ݊ோோబ = Ͳ.ͲͻͶ͹. (6) 
If we compare these values with their order estimation above, we see that the values are 
acceptable and the curve fit is as well, see Fig. 1a. 
Now, we may proceed with OPG parameters. The difference is that if we use only the 
second reaction of RANKL-RANK-OPG reaction scheme (1), we do not know how initial 
OPG concentration influences the number of bonds between RANKL and RANK. However, 
this influence is mediated by a decrease in number of available ligands RANKL by binding 
with OPG. Because OPG binds with higher affinity to ligand RANKL than this ligand to its 
receptor RANK (otherwise the decoy effects of OPG would be very limited), it will be 
assumed that OPG binds to RANKL more rapidly than the competiting reaction. The reason 
for this is again in the need of analytic solution of differential equations that govern the 
kinetics of mentioned processes (it was not possible to solve the full system of two 
differential equations (2) so the mentioned simplification was needed; again, from the 
results that follow it seems reasonable). Thus, the influence of levels of osteoprotegerin on 
the ܴܴ concentration may be mediated by an appropriate modification of initial 
concentration of RANKL which in turn affects the resulting ܴܴ concentration. Schematically:  ʹ୬ୢݎ݁ܽܿݐ݅݋݊	݅݊	ሺͳሻ → [OPG]ሺݐሻ 
and consequently [RANKL଴] = [OPG]ሺ߬୓୔ୋሻ, which is used in  ͳୱ୲ݎ݁ܽܿݐ݅݋݊	݋݂	ሺͳሻ → [RR][߬଻ୢୟ୷ୱ] 
were ߬୓୔ୋ is a time to be determined. 
www.intechopen.com
 Theoretical Biomechanics 194 
   
Fig. 1. RANKL and OPG fitted solutions (blue curves) by least squares method to data 
measured (dots) by Quinn et al. (Quinn et al, 2001). Firstly, nୖୖ as a function of nୖ୅୒୏୐బ is 
determined and consequently nୖୖ as a function of n୓୔ୋబ, created by embedding dependency 
of [RANKL] on [OPG] and of [RR] on [RANKL] concentration, was found. 
The already determined parameters from the RANKL setting will be used and only the yet 
unknown will be determined, i.e.  ߜିଶୖୖ୓, ߜାଶୖୖ୓, ߬୓୔ୋୖୖ୓, ݊ோைబ , 
Again, the least squares in the case of OPG give the following estimates (based on data from 
Quinn and the fact that molecular weight of RANKL is ͷͷ	ͳͲଷ and of OPG ʹͲ	ͳͲଷ):  
 ߜିଶୖୖ୓ = ͷ.ͺ͸	ͳͲିଵଽ, ߜାଶୖୖ୓ = ͳʹ.ͻ͸, ߬୓୔ୋୖୖ୓ = ͳͳ.͵͸, ݊ோைబ = ͸.ͳ͵ͷ. (7) 
Also, the values are admissible and the curve fit is reasonable (the function here is much 
more complex because OPG concentration is firstly used to determine an initial RANKL 
concentration for a consecutive reaction that finally gives [RR] outcome), see Fig 1b. 
If the mentioned results of parameter estimation are combined, all the needed values of 
parameters of RANKL-RANK-OPG model (3) may be inferred:  ߜିଵୖୖ୓ 				= ݇ିଵ݇ାଵ[RANKLୱ୲ୟ୬ୢ] = Ͷ.ͻʹͳͲି଺,ߜିଶୖୖ୓ 				= ݇ିଶ݇ାଵ[RANKLୱ୲ୟ୬ୢ] = ͷ.ͺ͸ͳͲିଵଽ,ߜାଶୖୖ୓ 				= ݇ାଶ݇ାଵ = ͳʹ.ͻ͸,ߚୖ୓ୖୖ୓ 				= ܥୖ୓[RANKLୱ୲ୟ୬ୢ] = [RO଴] + [OPG଴][RANKLୱ୲ୟ୬ୢ] = ͸.ͳ͵ͷ + ݊ை௉ீబ ,ߚୖୖୖୖ୓ 				= ܥୖୖ[RANKLୱ୲ୟ୬ୢ] = [RR଴] + [RANKL଴] − [OPG଴][RANKLୱ୲ୟ୬ୢ] = Ͳ.ͲͻͶ͹ + ݊ோ஺ே௄௅బ − [OPG଴],ߚୖ୏ୖୖ୓ 				= ܥୖ୏[RANKLୱ୲ୟ୬ୢ] = [RK଴] − [RANKL଴] + [OPG଴][RANKLୱ୲ୟ୬ୢ] = ͳ.Ͳ͵͹ − ݊ோ஺ே௄௅బ + ݊ை௉ீబ ,߬଻ୢୟ୷ୱୖୖ୓ 				= Ͷ.͸Ͷ.
 (8)
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   The predicted effects of RANKL and OPG serum levels on bone density [RANKL] ቂ୮୫୭୪୪ ቃ [OPG] ቂ௣௠௢௟௟ ቃ nୖୖ [1]  normalised bone density [1] 
0.84 (standard)  1.8 (standard)  0.790  100% (0.811)  
4.55  1.8  1.132  76.9%(0.624) 
0.1  1.8  0.13  **172.6% (1.40) 
0.84  6.9  0.276  **152.9% (0.1.24) 
0.84  0.6  0.892  92.5% (0.75) 
Table 1. The predicted effects of the RANKL-RANK-OPG pathway on bone density. nୖୖ is a 
result from the RANKL-RANK-OPG pathway model, and consequently, bone density (the 
number in parentheses in the last column) is predicted from the presented thermodynamic 
bone remodelling model based on the calculated nୖୖ. The asterisk in the front of values 
notices that it may be necessary to intermit the treatment after a certain time: * - after a 
longer time, ** - after a shorter period. Simulated or predicted data by model that are bold 
are in accordance with data found in literature – (Kudlacek et al, 2003).   
Interconnection between this RRO model and bone remodelling model is mediated by [RR]. 
The concentration of ܴܴ influences the value of parameter ߚଵ in the developed 
thermodynamic bone remodelling model, see (Klika and Maršík, 2010). There are different 
normalisations used in these two mentioned models and we assume that in the case of 
standard values of RANKL and OPG, the parameter ߚଵ should have its standard value 
(corresponding to ``healthy'' state). Further, the typical normalised concentration of ܴܴ in 
bone remodelling model is ݊ோோ ∈ ሺͳ.͵ͷ,ͳ.Ͷͳሻ in standard state (see (Klika and Maršík, 2010)). 
Thus:  
 ߚଵ = ͳ.Ͷͳ/Ͳ.͹ͻ݊ோோ − Ͳ.ͺͳ, (9) 
which gives the value ߚଵ = Ͳ.͸ for standard values of RANKL and OPG because ݊ோோ under 
these condition equals Ͳ.͹ͻ and ݊ோோ is a result of the interaction in RANKL-RANK-OPG 
pathway at time ߬଻ୢୟ୷ୱୖୖ୓ . As can be seen, the value of ݊ோோ influences only ߚଵ, i.e. it acts only as 
a modification of initial conditions of the bone remodelling model. However, it will be seen 
in the results below that it sufficiently captures the influence of the whole pathway. 
The increase in ligand concentration RANKL should lead to an increase in osteoclast 
formation, and consequently, the decrease of bone tissue density, and conversely, 
osteoprotegerin OPG prevents osteoclastogenesis. Modelling of this pathway is carried out 
through solving kinetic equations (2) with the above mentioned parameter values (8). 
Consequently, the output value of ݊ோோ is used as an input variable in the bone adaptation 
model – (9). Tab. 1 gives an idea of how the added RANKL-RANK-OPG pathway may 
influence bone density (percentual changes of ݊ோோ are more or less in accordance with data 
found in Quinn et al. (Quinn et al., 2001). 
2.2 Incorporation of PTH effects into the bone remodelling model 
The parathyroid hormone plays an important role in bone remodelling (see introduction). 
Again, the discovery of the essential control RANKL-RANK-OPG pathway enabled to  
describe in higher detail the influence of PTH on bone adaptation process. Robling mentions 
that PTH effect is ``translated'' into RANKL (Robling et al, 2006), more precisely PTH 
promotes RANKL formation (Martin, 2004). Fukushima et al. studied in vitro responses of 
the RANKL expression to PTH (Fukushima et al, 2005). They clearly showed that RANKL 
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levels are dose-dependent on PTH concentrations in vitro (in the studied range ͳͲିଽ	ܯ-ͳͲି଺	ܯ). Using this data, the influence of PTH into the presented bone remodelling model 
will be incorporated. 
As was mentioned, PTH promotes RANKL expression. Thus, we may describe this fact 
using the following interaction:  
 ܲܶܪ + ܴܣܰܭܮ୮୰୭ୢ୳ୡୣ୰ୱ + ܵݑܾݏݐݎܽݐݑ݉ ୩±భርሮ 	ܴ ܣܰܭܮ + ܴܣܰܭܮ୮୰୭ୢ୳ୡୣ୰ୱ, (10) 
where ܴܣܰܭܮ୮୰୭ୢ୳ୡୣ୰ୱ represents the group of cells that are expressing RANKL and a 
mixture of substances needed for ligand RANKL production is denoted as ܵݑܾݏݐݎܽݐݑ݉. 
Again, the differential equation describing kinetics of PTH concentration can be derived:  d[PTH]d߬ = −[PTH]ሺߚୗ୳ୠୱ୲୰୔୘ୌ + [PTH]ሻ + ߜିଵ୔୘ୌሺߚୖ୅୒୏୐୔୘ୌ − [PTH]ሻ, (11)
 where  ߜିଵ୔୘ୌ = ݇ିଵ݇ାଵ[RANKLୱ୲ୟ୬ୢ] ,ߚୖ୅୒୏୐୔୘ୌ 				= ܥୖ୅୒୏୐[RANKLୱ୲ୟ୬ୢ] = [RANKL଴] + [PTH଴][RANKLୱ୲ୟ୬ୢ] ,ߚୗ୳ୠୱ୲୰୔୘ୌ = ܥୗ୳ୠୱ୲୰[RANKLୱ୲ୟ୬ୢ] = [Substr଴] − [PTH଴][RANKLୱ୲ୟ୬ୢ] .
 (12)
 
 
Fig. 2. PTH fitted solution (blue curve) by the least squares method to data measured (dots) 
by Fukushima et al. (Fukushima et al, 2005).  
Again, this differential equation can be rewritten into (4) where ܣ = ͳ, ܤ = ߚୗ୳ୠୱ୲୰୔୘ୌ +ߜିଵ୔୘ୌ, ܥ = ߜିଵߚୖ୅୒୏୐. Thus, the analytical function that describes the evolution of PTH 
concentration in time from its initial concentration is known. The mentioned in vitro data 
from Fukushima et al. will be used for estimation of these parameter values using the least 
square method. Finally, the initial concentration of PTH influences RANKL concentration 
after 10 days in culture:  [RANKL] = ߚୖ୅୒୏୐୔୘ୌ − [PTH]. 
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The least squares method gives the following results (see Fig. 2):  ߜିଵ୔୘ୌ = Ͳ.ͳͶͷ, ߬ଵ଴ୢୟ୷ୱ୔୘ୌ = ʹ͸.ͳ͹, ݊ௌ௨௕௦௧௥బ୔୘ୌ = Ͳ.Ͳͳͺ. (13)
In vitro behaviour may significantly vary from in vivo observation. Usually, the range of 
concentration found in humans is much narrower than examined in vitro. A relation 
between in vitro and in vivo study will be found. Firstly, it is needed to determine standard 
in vivo serum level of PTH in humans. Khosla et al. state that PTH serum levels in humans 
are in Ͳ − ͸ ௣௠௢௟௟  (Khosla et al, 1998). Further, Jorde et al. mentions that standard in vivo PTH 
level in non-smokers is ͵.͸ ௣௠௢௟௟ = ͵͵.ͺͶ ௣௚௠௟ (Jorde et al, 2005), where the fact that ܯ ୔ܹ୘ୌ =ͻͶͲͲ	daltons was used (Potts, 2005). Now, we need to find a study that would capture PTH 
effects on bone remodelling. Charopoulos et al. studied effects of primary 
hyperparathyroidism in both calcemic and non-calcemic groups (Charopoulos et al, 2006). 
They mention normal PTH levels to be ͵͹.ͳ͵ ௣௚௠௟ and in the case of the non-calcemic 
hyperparathyroidism group, PTH levels were significantly higher ͻ͹.Ͳͻ = ௣௚௠௟. Moreover, 
these values significantly correlated to BMD (bone mineral density). 
The idea is similar as in the previous case, the influence of PTH on bone density is mediated 
by RANKL-RANK-OPG pathway. The predicted value of RANKL based on PTH level will 
be used as an input into RRO model that will consequently translate this influence into the 
appropriate change in number of active osteoclasts. 
If one uses in vitro equivalent of in vivo standard level of PTH equal to ͷ	ͳͲିଽܯ and ݊ோ஺ே௄௅బ = ͳ.͵ͳ (again these values are opted to get the described in vivo effect of PTH 
concentration and that standard PTH values would lead to standard RANKL concentration 
and consequently also ``healthy'' bone density) we get similar results as observed in 
Charopoulos et al. study - see Tab. 2. 
We see that in normal range of PTH ʹͷ-Ͷͷ ௣௚௠௟ the predicted bone density varies slightly, see 
Tab. 2. However, disease state such as primary hyper-parathyriodism with PTH levels 3 
times higher than normal (ͻ͹.Ͳͻ ௣௚௠௟) the BMD dropped by 7-ͳͷ% in the tibia and by ͳͷ% in 
the lumbar vertebrae (Charopoulos et al, 2006). The presented model estimates a decrease in 
bone density by ͳʹ.ͺ% after such an increase in PTH. 
 
The predicted effects of PTH serum levels on bone density 
 [PTH] ቂ୮୥୫୪ቃ  normalised bone density   [1] 
25   102,8% (0.834)  
34 (standard)   100% (0.811)  
45   97.0%(0.787) 
97   87.3% (0.708) 
Table 2. The predicted effects of PTH serum levels on bone density. PTH influences RANKL 
expression, which in turn influences osteoclastogenesis. Consequently, bone density is 
predicted from the presented bone remodelling model based on the calculated [RR]. 
Simulated or predicted data by model that are bold are in accordance with the data found in 
literature – (Charopoulos et al, 2006; Jorde et al ,2005).   
2.3 Incorporation of NO effects into the bone remodelling model 
Nitric oxide is a small molecule that can freely diffuse across cell membrane without any use 
of channels (and thus without any control from cell). Probably this easy access is reason for 
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its signalling function. Also, because there is no need of passive or even active 
transportation across membrane it provides very fast communications. From the mentioned 
nature of signalling molecule NO, it is evident that it plays role in many processes in body, 
and concretely, it influences bone remodelling. 
There has been a quite thorough investigation of NO action on bone remodelling. Before the 
discovery of the RANKL-RANK-OPG pathway, van't Hof already carried out an in vitro 
experiment showing that NO plays a significant role in bone resorption by inducing 
apoptosis of osteoclast progenitors and supressing osteoclast activity (van’t Hof and 
Ralston, 1997). NO also seems to have a significant effect in inflammation-induced 
osteoporosis (such as rheumatoid arthritis), where NO production is increased, and 
consequently, bone density decreased (Armour et al, 1997). Wimalawansa et al. studied the 
effect of NO donor (concretely nitroglycerin) treatment on BMD change in rats. After 
treatment, they had significantly lower BMD and femur weights and also the influence of 
NO on the trabecular and cortical bone - loss of trabecular bone volume and decrease in 
cortical area in cross-section were prevented by the administration of nitroglycerin 
(Wimalawansa et al, 1997). Van't Hof and Ralston give a very nice overview of the NO role 
in bone - how nitric oxide is created, in what form, mechanism of NO action on bone 
remodelling, effects of NO on bone resorption (activation of inducible nitric oxide synthase - 
iNOS - pathway is essential for IL-1 stimulated bone resorption), and mention several in 
vivo animal models that exemplify this behaviour (van’t Hof and Ralston, 2001). Again, the 
discovery of RANKL and OPG enabled a more detailed study of NO effects on bone 
remodelling. Robling mentions that NO suppresses the expression of RANKL and promotes 
the expression of OPG (Robling et al, 2006). Both these effects lead to the decrease of bone 
resorption. Fan et al. carried out an in vitro study where a dose-dependent response to NO 
in both RANKL and OPG production has been shown (Fan et al, 2004). Rahnert et al. 
studied the influence of ʹ% exercise (ʹͲͲͲͲߤߝ) with 10 cycles/min (thus approximately ͹ͲͲͲߤߝݏିଵ), observed that mechanical loading represses RANKL production (i.e. 
resorption), and that nitric oxide influences this repression (Rahnert et al, 2008).  
Thus the in vitro effects of NO are rather known; however, there is lack of clinical studies 
with concrete effects of NO on bone quality. Fortunately, there is a group that has recently 
carried out a control study aimed on NO effects on bones in humans (the NOVEL clinical 
study - http://clinicaltrials.gov/show/NCT00043719). They performed a pilot study of NO 
effects on humans (surgically induced menopause women), which had a promising results. 
Nitroglycerin has similar maintenance effects as estrogen on BMD (Wimalawansa, 2000). 
Further, there is a nice review by Wimalawansa on the treatment of bone osteoporosis with 
NO: nitric oxide is a very reactive agent (half life is 1 second) and thus it has a very localised 
effects; after menopause, the circulating NO is significantly lower than before (can be 
rectified after hormonal therapy); NO donors have high potential as a novel therapeutic 
agent in bone diseases (follows from clinical studies of his group); NO seems to have a 
biphasic effect on bone quality - high levels of NO generation decrease BMD whereas lower 
levels increase BMD (from here it implies that the possible therapeutic window is <͵ͷ	݉݃/݀ܽݕ - in this range the treatment is beneficial on skeleton); animal studies are 
confirming that NO has a biphasic effect on BMD. Further, that nitroglycerin is superior to 
the other 10 studied NO donors, and showing what is the in vivo dose-response to 
nitroglycerin (Wimalawansa, 2007). 
An estimation of NO effects on bone may be carried out (there is yet no clinical study that 
we may refer to) that will be based on in vitro studies and on studies with NO donor 
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delivery in humans and animals as mentioned in the previous paragraph (in the animal 
study with dose response to NO donors, the same levels of nitroglycerin per kilogram of 
body weight were distributed and the same biphasic effect with the same threshold - ଷହ௠௚଻ହ௞௚ ≈ Ͳ.ͷ௠௚௞௚  of nitroglycerin per day - were observed as in humans). 
For a description of NO influences on bone remodelling, the following reaction scheme will 
be used. It is based on the previously mentioned observation:  
 
ܱܰ + ܴܣܰܭܮ ୩±భርሮ 	ܴ ݁݉ܽ݅݊݅݊݃_݌ݎ݋݀ݑܿݐ,ܱܰ + ܱܲܩ୮୰୭ୢ୳ୡୣ୰ୱ + ܵݑܾݏݐݎܽݐݑ݉ 	୩±మርሮܱܲܩ + ܱܲܩ୮୰୭ୢ୳ୡୣ୰ୱ, (14) 
where ܴ݁݉ܽ݅݊݅݊݃_݌ݎ݋݀ݑܿݐ represents inactivated RANKL. Again, we may simply obtain 
differential equations describing the kinetics of these interactions. Because the influence of 
NO levels are relatively small (max ͸% increase in BMD (Wimalawansa, 2007)), we may 
separate the influence of NO on RANKL and on OPG, and their collective effect can be 
obtained by summing the individual ones (confirmed by the numerical solution of both 
ODEs at once and compared with separated effects). By the same technique (least squares - 
Fig. 3) as in previous cases, the unknown parameters of the mentioned scheme may be 
determined (normalisation in the two differential equations is quite different):  ܴܣܰܭܮ: ߜିଵ୒୓,ୖ = ʹ.Ͳ͸ ͳͲିଵଶ, ߬ଶସ୦୒୓,ୖ = ͳ.Ͳ͵͸, ݊ோ௘௠௔௜௡௜௡௚_௣௥௢ௗ௨௖௧బ = Ͳ.ͻ͵Ͳ,ܱܲܩ: ߜିଵ୒୓,୓ = ͷʹͺ.ʹ, ߬ଶସ୦୒୓,୓ = ͳ.͸ ͳͲିଷ, ݊ௌ௨௕௦௧௥బ = ͺ.ͷͲ.  (15)
 
 
Fig. 3. NO fitted solutions (blue curve) by the least squares method to data measured (dots) 
by Wimalawansa (Wimalawansa, 2007) - NO influences both RANKL and OPG expression. 
The in vivo standard was determined from a graph in (Wimalawansa, 2007): Ͳ.ͲͶͶ	௠௚௞௚  per 
day of nitroglycerin - there is no BMD change observed. This dosage of nitroglycerin 
treatment (and consequently NO levels) in ovariectomized rats is assumed to correspond to 
standard in vivo levels of NO (or a more stable ܱܰଷ). Here, the previously used linear 
relation between in vitro and in vivo scales does not suitably characterise the observed 
relationship. Therefore the following logarithmic relation was proposed and served for 
finding a suitable [NO୧୬_୴୧୲୰୭_ୱ୲ୟ୬ୢ] (so that NO would have the same effects on bone 
remodelling as observed in vivo):  
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[OPG଴]ୖୖ୓ = ݊ை௉ீೞ೟ೌ೙೏݂݅ݐܱܱܰܲܩሺ[NO୧୬_୴୧୲୰୭_ୱ୲ୟ୬ୢ]ሻ ⋅⋅ ݂݅ݐܱܱܰܲܩሺሺͳ + lnሺ[NO୧୬_୴୧୴୭]/[NO୧୬_୴୧୴୭_ୱ୲ୟ୬ୢ]ሻ[NO୧୬_୴୧୴୭_ୱ୲ୟ୬ୢ]ሻ 
where ݂݅ݐܱܱܰܲܩሺ[NO୧୬_୴୧୲୰୭]ሻ is a function describing in vitro effect of NO concentration on 
OPG, ݊ை௉ீೞ೟ೌ೙೏ = [୓୔ୋ౩౪౗౤ౚ][ୖ୅୒୏୐౩౪౗౤ౚ] is a normalised standard OPG molar concentration, [NO୧୬_୴୧୴୭] 
represents in vivo NO level corresponding to served dosage of nitroglycerin, [NO୧୬_୴୧୴୭_ୱ୲ୟ୬ୢ] 
is the standard in vivo NO level, 
௡ೀುಸೞ೟ೌ೙೏௙௜௧ேைை௉ீሺ[୒୓౟౤_౬౟౪౨౥_౩౪౗౤ౚ]ሻ represents a scaling factor 
guaranteeing linkage between this model of NO influence and RANKl-RANK-OPG model 
(with different normalisation). Thus, this relation means that a logarithmically different 
response in vivo to NO levels than in vitro is assumed. Similarly for RANKL:  
 
ܴܣܰܭܮ:	[NO୧୬_୴୧୲୰୭_ୱ୲ୟ୬ୢ]୒୓,ୖ = Ͳ.Ͳ͵͸,ܱܲܩ:	[NO୧୬_୴୧୲୰୭_ୱ୲ୟ୬ୢ]୒୓,୓ = ͳ.Ͳͳ.  (16) 
From results in Tab. 3, it can be seen that the simulated effects of NO on bone density are 
very similar to those shown in (Wimalawansa, 2007). As was mentioned, after menopause a 
decrease in NO levels is observed. As can be seen from Tab. 3, this may also slightly 
contribute to the increase in bone resorption. Moreover, there seems to be a possibility to  
 
   The predicted effects of NG treatment on bone density 
 NG (nitroglycerin) ቂ୮୥୫୪ቃ per day  n୓୔ୋ [1]  nୖ୅୒୏୐ [1]  normalised bone density [1] 
 0.001   0.157   1.078   92.4% (0.749)  
0.02   0.21   1.016   98.3% (0.797) 
0.044 (standard)   0.233   1   100% (0.811)  
0.1   0.250   0.984   102.0%(0.827) 
0.5   0.281   0.953   106.0% (0.860) 
Table 3. The predicted effects of nitroglycerin (NO donor) treatment on bone density. NO 
promotes OPG expression and suppress the RANKL production - the same behaviour can 
be observed here. Consequently, bone density is predicted from the presented bone 
remodelling model based on the calculated [RR]. It is worth mentioning that NO has 
biphasic effect on bone, and in the window here studied, i.e. NO donor nitroglycerin is 
served up to Ͳ.ͲͶͶ୫୥୩୥  per day, has anabolic effects. Simulated or predicted data by model 
that are bold are in accordance with data found in literature – (Wimalawansa, 2007).   
decrease these unwanted effects by nitroglycerin treatment, but only to some extent because 
when the dosage increase approximately over Ͳ.ͷ	௠௚௞௚  per day it ceases to be beneficial. On 
the contrary, it may be deleterious (so-called biphasic effect of NO on skeleton; it may still 
have a positive impact on cardiovascular system etc.). 
2.4 Notes on estradiol ૚. ૛૞ሺ۽۶ሻ૛۲૜(vitamin D) and TGF-઺૚ 
Estradiol 
Analogously to incorporation of PTH effects on bone remodelling through RANKL-RANK-
OPG pathway can be carried out so it will be omitted here and can be found in (Klika et al, 
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2010). However, the simulation results will be shown even with changing levels of estradiol 
to demonstrate the usage of this model – see section 3. ૚. ૛૞ሺࡻࡴሻ૛ࡰ૜(vitamin D) 
Similarly, as in the previous sections, we wanted to incorporate also the influences of 
vitamin D (more precisely ͳ.ʹͷሺOHሻଶDଷ) and TGF-ߚଵ on the bone remodelling phenomenon. 
However, both these factors had to be omitted (for different reasons). 
Vitamin D seems to be quite a significant factor acting on bone remodelling, e.g. seasonal 
effects due to sun exposure (and consequently increased vitamin D production in body) are 
observed (Saquib et al, 2006). Tanaka et al. showed that vitamin D promotes active 
osteoclast formation in vitro (Tanaka et al, 1993). There are in vitro studies that confirm 
again the mediation of vitamin D effects by the RANKL-RANK-OPG pathway (Martin, 
2004). Moreover, it seems that there is a clinical study about to start that documents the 
mentioned influence on RANKL in humans but not enough of information is available yet. 
But the problem is that there are many other studies that do not observe any significant 
influence of vitamin D levels on bone tissue, e.g. (Lips et al, 2001). One possible reason for 
these discrepancies in the observed results may lie in problems with its measurement. 
Carter mentions that there are several different methods for its determination and give 
significantly different results (Carter et al, 2004). In the year 2007, a thorough recherche was 
carried out by University of Ottawa, Evidence-based Practice Center for Agency for 
Healthcare Research and Quality (Cranney et al, 2007). They mention that 11 out of 19 
studies are confirming that there is a significant correlation between vitamin D and bone 
mineral density, but also the remaining 8 are stating that there is no such effect. 
Due to this ambiguity in clinical studies, we do not incorporate vitamin D into the presented 
model. If there is more infomation in future that would clarify these discrepancies, the 
vitamin D effect may be added by the same procedure as was used in estradiol, PTH, and 
NO. 
TGF-ࢼ૚ 
There is clear evidence that this growth factor plays a significant role in the control of bone 
remodelling. Murakami et al. showed that the OPG expression is promoted dose-
dependently by TGF-ߚଵ (Murakami et al, 1998) and Quinn et al. further found that RANKL 
expression is down-regulated by actuation of this growth factor (Quinn et al, 2001). 
However, clinical data collected by Zhang et al. show a fairly different behaviour of effect 
(Zhang et al, 2009). This different behaviour may be due to biphasic effect of TGH-ߚଵ that 
was observed by Karst et al. in vitro (Karst et al, 2004): TGF-ߚଵ in lower concentration 
elevated and in higher decreased the RANKL/OPG ratio. However, still from the 
mentioned clinical study it follows that actuation of TGF-ߚ on bone remodelling is not 
mediated only by the RANKL-RANK-OPG pathway because response to TGF-ߚ seems to be 
more complex. It is known that this factor also induces ܯܱܰܥ apoptosis (Mundy et al, 1995; 
Murakami et al, 1998), which is described by ܬଷ in the presented model. Further, TGF-ߚଵ 
attracts osteoblastic precursors by chemotaxis to the resorbed site (Mundy et al, 1995). Even 
though transforming growth factor ߚ is a component of local factors ܮܨ in the presented 
model, the influence of MNOC apoptosis can be described through ܬଷ, and actuation on 
RANKL-RANK-OPG pathway as well, still the effects on bone tissue are not in accordance 
with clinically observed behaviour. Thus, the influence of TGF-ߚ on bone remodelling 
cannot be described by the presented model in enough detail - it is a limitation of the model. 
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3. Examples of predictions of bone remodelling based on the presented 
model 
We may now simulate the response of bone remodelling to changing environment, both 
mechanical and biochemical. Similarly, as was described in (Maršík et al, 2010), density 
distribution patterns may be obtained using Finite Elements Method (FEM). The results 
from the previous section will be used. 
To demonstrate the usage of the presented model, a prediction of density distribution in 
human femur was carried out (the FE model of femur consists of 25636 3D 10 node 
tetrahedron elements). As an initial state, a homogeneous distribution of apparent density 
throughout the whole bone was used (1.8 g/cm3). Since each iteration is calculated by 
solving differential equations representing the whole model of bone remodelling, it is 
actually a time evolution of bone remodelling in bone (Ansys v11.0 program was used to 
calculate the mechanical stimuli in each element). Real geometry was gained from a CT-scan 
and external forces were applied in the usual directions and magnitude - including muscle 
forces acting on the femur (Heller et al., 2005). This technique was used for all computed 
results included in this chapter. One may observe that cortical bone (the denser part of bone) 
and cancellous bone are formed (and maintained) as a consequence of mechanical stimuli 
distribution in human bone. 
It was needed to use a relation between predicted bone density and mechanical properties 
(elastic moduli). There is a great disparity in the proposed elastic-density relationships 
(Helgason et al, 2008; Rice et al, 1988; Rho et al, 1993; Hodgskinson and Currey, 1992). We 
used a most common relationship for the human femur because the relation seems to be 
site-specific (Helgason et al, 2008):	E ∝ ߩଶ, which defines through bone density the 
constitutive relation being considered. If a different power law is used, the pattern of 
density distribution still remains the same. 
As was mentioned in the introduction, the most important mechanical stimulus for 
maintaining bone tissue is the most common daily activity - walking. Nowadays, many 
people have sedentary jobs and that is why they spent less hours by walking than would be 
appropriate. An example of a person whose walking activity is around 55% of a healthy 
standard (1.5 hours of walking compared to 2.75h) is shown - inappropriate loading leads to 
decrease in bone density, see Fig. 4. Naturally, a possible treatment would be in spending 
more time walking (1.25h more) or similar effect can be reached by running, which is a 
higher osteogenic stimuli - 30 minutes of running every other day will compensate for the 
disuse - see Fig. 4. 
Hyperparathyroidism was chosen as an example of biochemical control of bone 
remodelling. As was discussed in section 2.2, during this disease, the PTH serum levels are ͻ͹ ௣௚௠௟, whereas a standard value is ͵Ͷ ௣௚௠௟. This should lead to a significant decrease in bone 
density. An example of a person who is physically active (correct mechanical stimuli on 
regular daily basis, i.e. approximately 20 000 steps per day) but suffers from 
hyperparathyroidism (serum level of PTH is ͻ͹ ௣௚௠௟) is depicted on Fig. 5. We may observe an 
expected decrease in bone density. Because mechanical loading has an osteogenic effect 
even in a disease state, we may try to increase bone density (possibly insufficiently) only 
with an increase in mechanical stimulation, 30 minute-running per every other day was 
chosen. The predicted improvement is depicted in Fig.5.  
During menopause, a decline in estradiol levels occur. In some women, the decrease is very 
dramatic (a drop bellow ͷ ௣௚௠௟ is observed, whereas a standard serum level is ͶͲ-͸Ͳ ௣௚௠௟) while 
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in some not (serum level remains above ʹͲ ௣௚௠௟), see (Klika et al, 2010). Further it was 
observed that, together with estradiol, there is a decline in nitric oxide levels - see section 
2.3. An example of a woman who is physically active (correct mechanical stimuli on regular 
daily basis, i.e. approximately 20 000 steps per day) but in a consequence of menopause has 
decreased serum levels of estradiol and nitric oxide (as mentioned above - estradiol: ʹ.ͷ ௣௚௠௟, 
NO level correspond to Ͳ.Ͳʹ௠௚௞௚  per day of nitroglycerin) is depicted in Fig. 6. The presented 
model predicts a decrease of ͺ% in bone tissue density, which does not seem to be 
osteoporosis yet. This may be because menopause is accompanied by more effects than 
these two mentioned and also most probably because they are less physically active (may be 
caused by pain). If we combine the ͺ% decrease (Fig. 6) caused by menopause alone with 
another ͻ% decline (Fig. 4) caused by improper loading, we get a significant drop by almost ʹͲ% in the overall bone density of the femur, which can be considered as osteoporotic state. 
One possible treatment of bone loss connected with menopause is treated with hormone 
therapy (HRT). Simulation of such a treatment that increased estradiol serum levels to ʹͲ ௣௚௠௟ 
(or by Ͳ.ͳͲ͹௠௚௞௚  per day of nitroglycerin treatment which is actually less expensive) is given 
in Fig. 6. Again, the importance of mechanical stimulation shown when increased physical 
activity (running 30 minutes every other day) increases bone density in similar fashion as 
HRT treatment (the same figure). And best results are reached when both effects are 
combined and even the original bone tissue density can be restored - Fig. 6.  
4. Conclusion 
A natural goal of the modelling of a process in the human body is to help in understanding its 
mechanisms and ideally to help in the treatment of diseases related to this phenomenon. For 
this reason, more detailed influences of various biochemical factors were added. Nowadays, 
the RANKL/RANK/OPG chain is deemed to be one of the most important biochemical 
controls of the bone remodelling process. The direct cellular contact of osteoclast precursor 
with stromal cells is needed for osteoclastogenesis. This contact is mediated by the receptor on 
osteoclasts and their precursor, RANK, and ligand RANKL on osteoblasts. Osteoprotegerin 
binds with higher affinity to RANK which inhibits the receptor-ligand interaction and as a 
result, it reduces osteoclastogenesis. Thus, the raise in OPG concentration results in a smaller 
number of resorbing osteoclasts, which leads to higher bone tissue density. The results 
discussed in the presented work have exactly the same behaviour. Similarly, the effects of 
RANKL, RANK, and estradiol were added to the mentioned model. Consequently, simulation 
capabilities were demonstrated on examples of diseases and their treatment. These results 
were partially validated by clinical studies found in literature. 
However, the impression that the presented model is able to simulate the bone remodelling 
process in the whole complexity is not correct. It has limitations, as mentioned below, in the 
spatial precision of the results (i.e. actual structure of bone tissue) and also some control 
mechanisms cannot be included (e.g. TGF-β effects, as was mentioned at the end of section 
2.4). But still, the model can be at least considered as a summary of known important 
factors, comprising the fundamental aspects of the currently known knowledge of the bone 
remodelling phenomenon, with some predictive capabilities and encouraging predictive 
simulations. Since the presented model is a concentration model, it cannot be used 
arbitrarily. The limitation is, of course, in the spatial precision of results. The minimal 
volume unit (finite element) should be sufficiently large to contain enough of all the  
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Fig. 4. Prediction of disuse effect on bone quality - simulation of insufficient loading (half of 
the recommended daily stimulation), treatment proposal - running (30 minutes every other 
day), and its simulation. Notice the change of bone mass (BM) of the whole femur.   
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Fig. 5. Prediction of the PTH effect on bone quality - simulation of hyperparathyroidism 
(ͻ͹ ୮୥୫୪ where normal PTH levels are ͵Ͷ ୮୥୫୪), treatment proposal - running (30 minutes every 
other day), and its simulation. Notice the change of bone mass (BM) of the whole femur. 
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Fig. 6. Prediction of the menopause effect on bone quality (estradiol levels decreased to ʹ.ͷ ୮୥୫୪ and NO to half of its normal level), treatment proposal, and its simulation - hormonal 
treatment (HRT), running (30 minutes every other day). Notice the change of bone mass 
(BM) of the whole femur.   
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substances entering the reaction schemes, namely osteoclasts and osteoblasts. It surely 
cannot be used on the length scales of BMU where it is no longer guaranteed that any 
osteoclast is present. There are approximately 107 BMU in a human skeleton present at any 
moment (Klika and Maršík, 2010) and, because bones have a total volume of 1.75l, there is 1 
BMU per 0.175 mm3 on average at any moment. In other words, the presented model cannot 
be used for length scales smaller than √Ͳ.ͳ͹ͷయ  mm3 and we recommend that it is not used on 
length scales below √Ͳ.ͷయ  mm3 ≈	0.8 mm. 
Ongoing applications of the model include simulations of the 3D geometries of the femur 
and vertebrae (FE models) under various conditions (both biochemical and mechanical). The 
preliminary results are encouraging and show the correct density distribution. Currently, 
we are working on bone modelling (change of shape of bone) model that would add the 
possibility to adapt bone to its mechanical environment as it is observed in vivo. Further, we 
would like to have a more detailed description of the inner structure of bone as an outcome 
of the model. Most probably, a homogenisation technique will be used for addressing this 
goal. Most importantly, a validation of the model‘s predictions (or finding limits of its 
application) should start in near future in cooperation with Ambulant Centre for Defects of 
Locomotor Aparatus in Prague. 
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